25 May 2013
Keywords: metformin, gr, meets, goal, ph, iii, trial
Article | 22 December 2003
Preliminary findings from a Phase III trial of Canada-based Bioavail andUS partner Depomed's Metformin GR, a once-daily extended-release
formulation of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 December 2003
24 May 2013
© 2013 thepharmaletter.com